Interferon alpha-2b and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial

American Journal of Medicine

Volumn 107, Issue 2, 1999, Pages 112-118

  Barbaro, Giuseppe ^a   Di Lorenzo, Gabriella ^a   Belloni, Giancarlo ^b   Ferrari, Luisella ^b   Paiano, Aldo ^c   Del Poggio, Paolo ^c   Bacca, Donato ^c   Fruttaldo, Luigi ^d   Mongiò, Franco ^d   Francavilla, Ruggiero ^c   Scotto, Gaetano ^e   Grisorio, Benvenuto ^e   Calleri, Guido ^f   Annese, Mauro ^g   Barelli, Andrea ^h   Rocchetto, Piero ^h   Rizzo, Giovanni ⁱ   Gualandi, Guido ^j   Poltronieri, Italo ^j   Barbarini, Giorgio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c GENERAL HOSPITAL   (Italy)

^d General Hospital   (Italy)

^e GENERAL HOSPITAL   (Italy)

^f AMEDEO DI SAVOIA HOSPITAL   (Italy)

^g General Hospital   (Italy)

^h General Hospital   (Italy)

ⁱ General Hospital   (Italy)

^j S ANNA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOBLOTTING; INTERFERON ALFA-2B; INTERFERON-ALPHA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0032838890     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(99)00160-6     Document Type: Article

References (28)

1. Davis G., Balart L., Schiff E., et al. Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized, controlled trial. NEJM. 321:1989;1501-1506.
2. Di Bisceglie A., Martin P., Kassianides C., et al. Recombinant interferon alpha therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. NEJM. 321:1989;1506-1510.
3. Schvarcz R., Weiland O., Wejstàl R., et al. A randomized controlled open study of interferon alpha-2b treatment of chronic non-A, non-B post-transfusion hepatitis. No correlation of outcome to presence of hepatitis C virus antibodies. Scand J Infect Dis. 21:1989;617-625.
4. Tine F., Magrin S., Craxi A., Pagliaro L. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol. 13:1991;192-199.
5. Reichard O., Andersson J., Schvarcz R., Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 337:1991;1056-1061.
6. Di Bisceglie A., Shindo M., Fong T., et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology. 16:1992;649-654.
7. Camps J., Garcia N., Riezu-Boj J., et al. Ribavirin in the treatment of chronic hepatitis C unresponsive to alpha interferon. J Hepatol. 19:1993;408-412.
8. Reichard O., Yun Z., Sonneborg A., Weiland O. Hepatitis C viral RNA titers in serum prior to, during and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol. 41:1993;99-102.
9. Brillant S., Garson J., Foli M., et al. A pilot study of combination therapy with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
10. Brillanti S., Miglioli M., Barbara L. Combination antiviral therapy with ribavirin and interferon alpha in interferon alpha relapsers and non-responders Italian experience . J Hepatol. 23:1995;13-16.
11. Schvarcz R., Yun Z.B., Sonneborg A., Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non response or non-sustained response to interferon alone. J Med Virol. 46:1995;43-47.
12. Reichard O., Norkrans G., Fryden A., et al. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
13. McHutchinson J.G., Gordon S.C., Schiff E.R., et al. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. NEJM. 339:1998;1485-1492.
14. Davis G.L., Esteban-Mur R., Rustgi V., et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. NEJM. 339:1998;1493-1499.
15. Okamoto H., Okada S., Sugiyama Y., et al. The 5′ terminal sequence of the hepatitis C virus genome. Jpn J Exp Med. 60:1990;167-177.
16. Shindo M., Di Bisceglie A.M., Cheung L., et al. Decrease in hepatitis C virus RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med. 115:1990;700-704.
17. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
18. Okamoto H., Sugiyama Y., Okada S., et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers application to clinical surveys and tracing infectious sources . J Gen Virol. 73:1992;673-679.
19. Okamoto H., Tokita H., Sakamoto M., et al. Characterization of the genomic sequence of the type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection. J Gen Virol. 75:1994;629-635.
20. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
21. Armitage P, Berry G. Statistical Methods in Medical Research, 3rd ed. Oxford, England: Blackwell Scientific, 1994.
22. Sarracco G., Rosina F., Abate M., et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon alpha-2b. Hepatology. 18:1993;1300-1305.
23. Davis G.L., Lau J.Y., Lim H.L. Therapy for chronic hepatitis C. Gastroenterol Clin North Am. 23:1994;603-613.
24. Patterson J.L., Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis. 12:1990;1139-1146.
25. Hayden F.C., Schlepushkin A.N., Pushkarskaya N.L. Combined interferon α-2, rimantadine hydrochloride and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother. 25:1984;53-57.
26. Maertens G, Stuyver L. Genotypes and genetic variation of hepatitis C virus. In: Harrison TJ, Zuckerman AJ, eds. The Molecular Medicine of Viral Hepatitis. New York: John Wiley & Sons Ltd. 1997:226-227.
27. Scotto G., Fazio V., Tantimonaco G. Pilot study of short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha interferon alone. Ital J Gastroenterol. 28:1996;505-511.
28. Schalm S.W., Brouwer J.T., Chemello L., et al. Interferon-ribavirin combination therapy for chronic hepatitis C. Dig Dis Sci. 41:1996;131S-134S.